Finally, these data could imply that ATO treatment might improve the prognosis and decrease the likelihood of cancer metastasis in a variety of cancers, and so treatment with arsenic trioxide could be a new option for tumour therapies with atypical TG2 expression, including colon, breast, stomach, leukaemia, lymphoma, oesophagus, pancreatic, pulmonary, and cervical cancers [32]. This evidence concerns the gene TGM2 and leukemia.